Hatteras Discovery
Hatteras Discovery is a venture capital firm based in Durham, North Carolina, focusing on early and seed stage investments in the life sciences and healthcare sectors. Established in August 2011 as a subsidiary of Hatteras Venture Partners, it primarily targets therapeutic areas such as ophthalmology, cardiovascular, pulmonary, anti-infectives, oncology, immunology, and orphan diseases. The firm aims to invest between $0.25 million and $1 million in portfolio companies located in North Carolina, emphasizing its commitment to supporting regional innovation in healthcare. Hatteras Discovery leverages the expertise and resources of its parent company, which has a broader focus on biopharmaceuticals, medical devices, and healthcare technologies, thereby enhancing its ability to foster the growth of emerging companies in the healthcare landscape.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries.
The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.